Drug intelligence / Profile preview

Tongfeng Kangning Tablets

Development stage: Unknown
Lead developer: Tianjin Tianzhong Pharmaceutical Technology
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Tongfeng Kangning Tablets (痛风康宁片) is a traditional Chinese medicine (TCM) candidate developed by Tianjin Tianzhong Pharmaceutical Technology for the treatment of acute gouty arthritis. The drug is specifically indicated for patients with the TCM syndrome pattern of damp-heat and blood stasis, which typically involves symptoms such as joint redness, swelling, and severe pain. It is currently undergoing a multicenter, randomized, double-blind, placebo-controlled Phase II dose-finding study (CTR20230298) in China to evaluate its efficacy and safety over a 7-day treatment course.

Other names: 痛风康宁片

Beyond the preview

Go deeper on Tongfeng Kangning Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongfeng Kangning Tablets.

Explore the full profile